Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.

Shima H, Miharu M, Osumi T, Takahashi T, Shimada H.

Pediatr Blood Cancer. 2010 Jul 1;54(7):1050-2. doi: 10.1002/pbc.22451.

PMID:
20146339
2.

Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.

Soler-Palacín P, Frick MA, Martín-Nalda A, Lanaspa M, Pou L, Roselló E, de Heredia CD, Figueras C.

J Antimicrob Chemother. 2012 Mar;67(3):700-6. doi: 10.1093/jac/dkr517. Epub 2011 Dec 21.

PMID:
22190607
3.

Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.

Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, Lortholary O, Jullien V.

Ther Drug Monit. 2011 Aug;33(4):464-6. doi: 10.1097/FTD.0b013e3182241b2b.

PMID:
21743382
4.

Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis).

Sanchez-Migallon Guzman D, Flammer K, Papich MG, Grooters AM, Shaw S, Applegate J, Tully TN.

Am J Vet Res. 2010 Apr;71(4):460-7. doi: 10.2460/ajvr.71.4.460.

PMID:
20367055
5.

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O.

Clin Infect Dis. 2008 Jan 15;46(2):201-11. doi: 10.1086/524669.

PMID:
18171251
6.

Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses.

Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC.

Am J Vet Res. 2006 Feb;67(2):296-301.

PMID:
16454636
7.

Voriconazole concentrations and outcome of invasive fungal infections.

Miyakis S, van Hal SJ, Ray J, Marriott D.

Clin Microbiol Infect. 2010 Jul;16(7):927-33. doi: 10.1111/j.1469-0691.2009.02990.x. Epub 2009 Oct 20.

8.

[Treatment with voriconazole for invasive fungal infection during chemotherapy for leukemia: doses and plasma concentration of voriconazole in children].

Fukushima K, Fujisawa M, Nakajima D, Matsunaga T, Hagisawa S, Kurosawa H, Sugita K, Arisaka O.

Rinsho Ketsueki. 2007 May;48(5):402-6. Japanese.

PMID:
17571586
9.

Voriconazole plasma monitoring.

Pasqualotto AC, Shah M, Wynn R, Denning DW.

Arch Dis Child. 2008 Jul;93(7):578-81. doi: 10.1136/adc.2007.118844. Epub 2008 Feb 5. Erratum in: Arch Dis Child. 2008 Oct;93(10):907.

PMID:
18252755
10.

Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).

Flammer K, Nettifee Osborne JA, Webb DJ, Foster LE, Dillard SL, Davis JL.

Am J Vet Res. 2008 Jan;69(1):114-21. doi: 10.2460/ajvr.69.1.114.

PMID:
18167096
11.

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR.

Pediatr Infect Dis J. 2002 Mar;21(3):240-8.

PMID:
12005089
12.

Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.

Peng LW, Lien YH.

Am J Kidney Dis. 2005 Jan;45(1):162-6.

PMID:
15696456
13.

Impact of therapeutic drug monitoring of voriconazole in a pediatric population.

Brüggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A.

Pediatr Infect Dis J. 2011 Jun;30(6):533-4. doi: 10.1097/INF.0b013e318204d227.

PMID:
21127454
14.

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.

Lutsar I, Roffey S, Troke P.

Clin Infect Dis. 2003 Sep 1;37(5):728-32. Epub 2003 Aug 7.

PMID:
12942409
15.

Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.

Chan HM, Duran SH, Walz PH, Ravis WR.

J Vet Pharmacol Ther. 2009 Jun;32(3):235-40. doi: 10.1111/j.1365-2885.2008.01030.x.

PMID:
19646087
16.

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, Amrein C, Dannaoui E, Loriot MA, Lillo-Le Louet A, Billaud EM.

Transpl Infect Dis. 2009 Jun;11(3):211-9. doi: 10.1111/j.1399-3062.2009.00384.x. Epub 2009 Mar 17.

PMID:
19302272
17.

Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.

Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J.

Antimicrob Agents Chemother. 2009 May;53(5):1793-6. doi: 10.1128/AAC.01316-08. Epub 2009 Feb 17.

18.

Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.

Howard A, Hoffman J, Sheth A.

Ann Pharmacother. 2008 Dec;42(12):1859-64. doi: 10.1345/aph.1L243. Epub 2008 Nov 18. Review.

PMID:
19017830
19.

Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.

Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH.

J Antimicrob Chemother. 2012 Nov;67(11):2717-24. doi: 10.1093/jac/dks258. Epub 2012 Jul 13.

PMID:
22796890
20.

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, Mauz-Körholz C, Preiss R.

Antimicrob Agents Chemother. 2010 Aug;54(8):3225-32. doi: 10.1128/AAC.01731-09. Epub 2010 Jun 14.

Supplemental Content

Support Center